Sartorius Stedim Biotech refines its strategy and aims for ambitious growth

Sartorius Stedim Biotech, a major player in the biopharmaceutical sector, is strengthening its strategy by focusing on innovation and efficiency. The company has announced new growth targets for the future. The emphasis is on developing high-growth, high-margin products and on emerging areas such as advanced therapies.

By 2025, global biopharmaceutical revenue is projected to surpass that of traditional therapies. With this in mind, Sartorius Stedim Biotech anticipates organic growth of 9% to 12% annually. The company also expects an annual improvement in its current EBITDA margin of 60 to 85 basis points.

This strategy will allow the company to remain a leader in a rapidly evolving industry, by better meeting the demands of efficiency and innovation.